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The complement system is of great importance in systemic lupus erythematosus. Complete genetically determined deﬁciencies
are with few exceptions reported for the various complement proteins, and most of the deﬁciency states are rare. Deﬁciencies of
the factors in the classical pathway are also associated with development SLE and SLE-like disorders. Most of the patients with
lupus present skin involvement. Approximately, 75–95% of patients with cutaneous lupus erythematosus respond to antimalarial
therapy and/or topical glucocorticosteroids. Immunosuppressive agents are usually considered a second-line approach in patients
withresistantdisease. In this study, we present the clinicalfeatures and determine the molecular basis responsible forthe complete
C4A and C4B deﬁciencies in a lupus patient presented subacute cutaneous lupus erythematosus and resistance to treatment.
1.Introduction
Lupus erythematosus is a chronic, autoimmune disease
resulting from an interaction of genetic, environmental, and
hormonal factors and characterized by a spectrum of clinical
forms with a variable evaluation from a localized cutaneous
form to life-threatening systemic form. Skin involvement
occurs in 70–85% of all patients with lupus [1]. Speciﬁc skin
lesions of cutaneous lupus erythematosus are classiﬁed as
acute cutaneous lupus erythematosus, subacute cutaneous
lupus erythematosus (SCLE), and chronic cutaneous lupus
erythematosus, according tothe clinicalcharacteristics of the
lesions [1].
Subacute cutaneous lupus erythematosus (SCLE) may
present with annular or papulosquamous cutaneous lesions
that are symmetrically located in the sun-exposed areas of
the body [2]. SCLE shows typical serological ﬁndings, with
anti-Ro (SS-A) antibodies present in up to 100% of patients
[3,4].However,antinuclearantibodies(ANAs),complement
C3/C4 deﬁciency, rheumatoid factor, circulating immune
complexes, lymphopenia, and thrombocytopenia can fre-
quently be detected. Severe neurological or nephrological
involvement is rare in SCLE, whereas mild musculoskeletal
involvement is commonly observed. It is well known that
some patients suﬀering from CLE develop extracutaneous
manifestations during the course of their disease; up to
30% of patients with SCLE show systemic involvement [5].
Most patients with SCLE can be suﬃciently treated with
photo protection, topical corticosteroids, antimalarials, or a
combination of these. When standard therapy fails, second-
line agents approach [6].
The complement system is a group of plasma and mem-
brane proteins that are sequentially activated via proteolytic
cleavages to defend against microbial infections [7, 8].
The complement system is of great importance in sys-
temic lupus erythematosus (SLE). Complement contributes
to inﬂammation and tissue damage in this disease, butseem-
ingly in paradox, deﬁciency of some complement proteins
dramatically increases the risk for SLE [9]. Deﬁciency states
withintheclassicalpathwayareassociatedwithincreasedrisk
to develop SLE and SLE-like disease [10].
Genetically determined complement deﬁciencies are
inborn errors and may have an impact on the development2 ISRN Rheumatology
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Figure 1: (a) Skin lesions of the patient showing on face and ﬁngers. (b) Serum complement C3 levels and SLEDAI scores before rituximab
therapy and at the end of the followup period.
of the immune system. Classical pathway deﬁciency has
led to diﬀerent hypothesis to explain roles for complement
in SLE pathogenesis [9]. Complement deﬁciency leads to
impaired handling of immune complex and inadequate
clearance apoptotic cell debris [11, 12]. Another hypothesis
suggests that the complement system has an important
role in the development of tolerance against self [13]. Also,
complement deﬁciency results in lack of normal B-cell
tolerance and provides production of autoantibodies [9]. In
addition, complement components are in some ways also
important for regulation of cytokine production, especially
Type 1 interferons have been shown to have a central role in
the pathogenesis of SLE [14, 15].
While the genetic basis for a majority of SLE cases is
polygenic, a homozygous deﬁciency in one of the early
complement components alone can be strong enough to
cause the disease, a situation similar to a single gene defect
in an autosomal recessive disease [16, 17]. Respectively, 93%
and 78% of patients with complete C1q and C4 deﬁciencies
eventually develop SLE or a lupus-like disease [18].
Genetically, the complement C4 gene located in the class
III region of the major histocompatibility complex (MHC)
on chromosome 6p21.3. About 40 protein variants for
complement C4 have been documented [19]. These proteins
are segregated into two classes, the acidic C4A and the basic
C4B. Each C4 gene either codes for a C4A or a C4B protein
[20]. C4A is believed to be important in the clearances of
immune complexes, and C4B is more powerful in propa-
gating the complement activation cascades. The complete
absence of both C4A and C4B proteins may therefore lead
to decreased ability of immune defense against microbes as
well as ineﬃcient disposal of immune complexes.
To date, 28 individuals with complete C4 deﬁciency from
19 families have been reported [21, 22]. Among them, 15
individuals developed SLE, 7 developed lupus-like diseases,
and four of the remaining subjects were only inﬂicted by
kidney diseases [23].
In this study, we present the clinical features and
determine the molecular basis responsible for the complete
C4A and C4B deﬁciencies in a lupus patient presented with
subacute cutaneous lupus erythematosus and progression
systemic form and resistance to treatment.
2.Case Report
Seventeen-year-old patient was a male born by parents
of non consanguineous marriage. He was diagnosed with
SCLE at the age of 15 years old and had local therapy
in dermatology clinic before admitting our clinic. Family
history for rheumatologic disease was negative. On physical
examination, his temperature 38.3, respiratory rate 38/min,
pulse rate 100/min, and blood pressure was found as
90/70mmHg. In auscultation, lungs were clear and the heart
sounds were normal. Abdominal palpation was normal. His
clinical presentation includedsevere malar rash with marked
photosensitivity and bullous lesions on the tips of ﬁngers
and hands (Figure 1). Skin biopsy was performed. There was
interface dermatitis with irregularityv and loss of basal cells.
Inthepapillary andupperreticulardermiswasaperivascular
and interstitial lymphocytic inﬁltrate. There was granular
deposition of Ig A, IgM, and C3 at the dermal-epidermal
junction. Also he has arthritis which described swelling,
tenderness, and pain on all small joints.
Laboratory tests showed an erythrocyte sedimentation
rate (ESR) of 100mm/h, C-reactive protein of <0.3mg/dL
(normal), hemoglobin of 11.1g/dL, hematocrit of 31%,
white blood cell count (WBC) of 4900/mm3 with normal
diﬀerential count, platelet count of 197000/mm3,s e r u m
urea of 25mg/dL, serum creatinine of 0.8mg/dL, albumine
of 3.5g/dL, total cholesterol of 106mg/dL, triglycerides of
57mg/dL,calciumof8.7mg/dL,sodiumof140mEq/L,pota-
sium of 4.7mEq/L, chloride of 107mEq/L, alanine amino-
transferase of 23U/L, and aspartate aminotransferase ofISRN Rheumatology 3
Table 1: The results of complement gene analysis.
C4A gene C4B gene
Exon Aminoacid mutation State Exon Aminoacid mutation State
9 S374Y h 26 L1120P h
23 E959D h 26 S1121C h
24 L986L h 26 I1124L h
28 D1176S h 26 H1125D h
28 A1205A h 28 A1205A h
28 V1207A h 28 V1207A h
28 L1210A h 28 L1210A h
10. Intron +19G > C h 19. Intron +33C > TH
12. Intron +23C > A h 20. Intron +7G > AH
h: Heterozygote, H: Homozygote.
16U/L. He had positivity for antinuclear antibody (1/1280),
positivity for anti-Ro/SSA antibodies and negative ds DNA.
Prior laboratory measurements showed no detectable C4
proteins, serum C3 levels were lower (77mg/dL) and C1q
inhibitor levels were normal. He had renal involvement
including moderate proteinuria. Kidney biopsies conﬁrmed
the presence of mesengioprolipherative glomerulonephri-
tis. Immunoﬂuorescence experiments showed mesangial
deposits of IgG,C3 (+++), IgA (+++) and C1q (+).
After he was diagnosed as SLE according to Amer-
ican college of Rheumatology (ACR) criteria, high-ose
“pulse” therapy was performed with methylprednisolo-
ne (30mg/kg/day for 3 days), followed by prednisone
(2mg/kg/day),Hydroxychloroquine(5mg/kg/day),and top-
ical therapy. He started Cyclophosphamide pulse therapy
(500mg/m2) because his complains were not resolved. After
from second dose of cyclophosphamide (750mg/m2), he
had urticarial lesions and stopped this therapy. He started
Mycophenolate sodium (720mg/day). In spite of these med-
ications, his skin lesions, arthritis were persisted; in addition,
myalgia and fatigue appeared. He received rituximab infu-
sions at a dose of 1 gram at days 1 and 15. He was premed-
icated with chlorpheniramine and acetaminophen 1 hour
prior to the rituximab infusion. In addition, a 100-mg dose
of intravenous methylprednisolone was given immediately
prior to the rituximab infusion. After rituximab therapy was
administered, oral low dose prednisolone (0,5mg/kg7day)
and Mycophenolate sodium were continued.
His complaints and laboratory values and SLEDAI scores
were improved signiﬁcantly after rituximab treatment, as
shown in Figure 1(b). Repeated laboratory measurements
showed no detectable C4 proteins, but serum C3 levels were
normal.
We performed both C4 gene mutation analyses. His
sample was kept in sterile EDTA bottle and stored at −80◦C.
Genomic DNAextraction was carried out using the standard
phenol/chloroform method. After PCR ampliﬁcation with
intron-exon binding primers, mutation was detected by
direct DNA sequencing method. These results were showed
in Table 1.
3.Discussion
We report a child with SLEand C4deﬁciencyandwith severe
skininvolvementthatprovedtobe subacutecutaneouslupus
erythematosus (SCLE). In our patient, the diagnosis of SLE
wasbasedonthepresenceofconstitutionalsymptoms, malar
rash, photosensitivity, oral ulceration, arthritis, anemia, a
high titer of ANA, and low C3, C4. The patient resistant to
initial therapies including HQK, Prednisolon and CYC.
Rituximab is a chimeric monoclonal IgG1antibody that
binds speciﬁcally to the CD20 antigen and mediates B-
cell lysis. Prior studies have shown that rituximab therapy
can be a safe and eﬃcacious addition to therapy with
standard immunosuppressive agents in patients with refrac-
tory childhood SLE [24–29]. In our case, Rituximab led to
a remarkable improvement of skin lesions, resulting in a
signiﬁcant decrease of the SLEDAI from 20 at the beginning
to 5 at the end of therapy. In addition, he exhibited a low
C4 level during the extended period of observation. Finally,
the genetic phenotyping of complement revealed that he was
homozygous for C4B deﬁciency.
SLE is a systemic autoimmune disease characterized by
the breakdown of immunotolerance and the production of
a wide range of autoantibodies that target multiple tissues
and organs [30]. Homozygous complement deﬁciencies
represent rare conditions. These are estimated to be found
in less than 1% of SLE patients [31, 32]. Respectively,
93% and 78% of patients with complete C1q and C4
deﬁciencies eventually develop SLE or a lupus-like disease
[22, 33]. In addition, the concordance rates for siblings with
homozygousdeﬁciencyofC1qorC4 todevelopSLE are 90%
and 80%, respectively, which are even higher than the rate in
monozygotictwins(26–60%)withothergeneticdefects[17].
C4A deﬁciency causes autoimmune disease, especially
systemic lupus erythematosus [34]. Indeed, approximately
15% of Caucasian SLE patients exhibit homozygous C4A
deﬁciency, whilst more than 50% of Caucasian patients with
SLE have heterozygous C4A deﬁciency [35]. C4B deﬁciency
caused autoimmune-associated diseases, such as systemic
lupus erythematosus, or diseases with an autoimmune
component, such as autism [36, 37].4 ISRN Rheumatology
Heterozygous and homozygous deﬁciencies of C4A were
present in 40–60% of SLE patients from almost all ethnic
groups such as Northern and Central Europeans, Anglo-
Saxons, Caucasians in the US, African Americans, Asian
Chinese, Koreans, and Japanese [38]. The major causes
for C4AQ0 in Caucasian and African SLE patients are the
presence of a mono-S RCCX module with a single, short
C4B gene and the 2-bp insertion into the sequence for
codon 1213 at exon 29 of the mutant C4A gene [39]. We
found heterozygous genetic deﬁciency of C4A gene, also
heterozygous and homozygous deﬁciencies of C4B in our
patient.
In conclusion, we report a case of C4B deﬁciency accom-
panied with SLE with therapy-resistant skin involvement.
Further studies are needed to clarify the relationship of C4B
deﬁciency and SLE which presented severe skin involvement.
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